Post-Stroke Secondary Prevention With Digital Monitoring
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Feb 14, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Post-Stroke Secondary Prevention With Digital Monitoring," is looking at how to help people who have had a stroke make important lifestyle changes to prevent another stroke. The researchers believe that using digital tools can help monitor patients closely after they leave the hospital, especially in the days and weeks right after their stroke. This is important because many patients struggle to quit smoking or change other habits that increase their risk of having another stroke. By focusing on both their physical health and mental well-being, the trial aims to create a more personalized support system for recovery.
To be eligible for this trial, participants must be between 18 and 80 years old, have recently experienced a stroke or a mini-stroke, and be current smokers. They should also be able to use a smartphone and live in an area with internet access. Participants will receive support tailored to their individual needs, including help with quitting smoking and managing stress or mood issues. Throughout the study, patients will be monitored closely, and they will have the chance to share their experiences, which will help healthcare providers offer the best possible care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female
- • At least 18 years of age and younger than 80 years;
- • Recent (≤ 15 days) clinically symptomatic ischemic or hemorrhagic stroke documented through brain imaging (CT or MRI) or a Transient Ischemic Attack with an Predictive Risk Score (ABCD2) ≥ 4;
- • Returning to the neurovascular unit for the standard care post-stroke follow-up visits;
- • National Institute Health Stroke Scale (NIHSS) \< 15;
- • modified Rankin scale ≤ 4;
- • No severe cognitive impairment as defined by the neurologist;
- • Current smokers (smoking at least 1 cigarette per day during the month before admission)
- • Able to use a smartphone
- • Living in an area with internet coverage
- • Written informed consent by the patient;
- • Coverage by the French National Health Insurance
- Exclusion Criteria:
- • Subarachnoid hemorrhage; Dementia syndrome or other central neurologic disorder;
- • Severe aphasia (NIHSS item 9 ≥ 2)
- • Severe visual impairment interfering with the completion of evaluations;
- • Severely impaired physical and/or mental health that, according to the neurologist, may affect the participant's capacity to participate in the study;
- • Individuals already undergoing treatment for tobacco cessation and/or SRADs at admission in the stroke unit;
- • Pregnancy or breastfeeding;
- • Inability to read French;
- • Individuals under legal protection or unable to express personally their consent
- • Participation in another protocol modifying the patient's follow-up status.
- • Person deprived of liberty
- • Person in emergency situation
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Patients applied
Trial Officials
Igor SIBON
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported